Interesting niche. But I don't see anything about production turnaround, and it appears that their CAR-T is designed to enhance mitigation of CCR-9. I think Gracell's 24 hour turnaround for CAR-T is a much better, even revolutionary, alternative, which I hope that lenz is a part of making that happen.
I see that they also provide CRISPR services. I think that lenz was developed with that gene-editing technology. But even so, I'm not comfortable with it, generally. And I see that GenScript also provides mRNA solutions, and I am becoming increasingly wary of that.
Lots and lots of potential with those technologies, but way too much opportunity for abuse of those capabilities.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.